We have located links that may give you full text access.
A novel method to combine assessment of benefit and harm: OMERACT 3x3 methodology applied to two active comparator trials.
Arthritis Care & Research 2018 April 26
INTRODUCTION: The Outcome Measures in Rheumatology (OMERACT) '3x3' method analyzes the occurrence of benefit and harm simultaneously at the individual patient level. We applied this method to two recent rheumatoid arthritis (RA) trial datasets.
METHODS: Treatment of Early Aggressive RA (TEAR) and the RA Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as no events, non-serious events, and serious events. Treatment efficacy was defined as good, moderate, or no response. A good treatment response without any events was labeled an 'unqualified success', and no treatment response but at least one adverse event an 'unmitigated failure'. Chi-square or exact tests assessed the association between benefit and harm, as appropriate.
RESULTS: In TEAR, 612 of 755 patients had response data at 48 weeks: 14% of patients experienced unqualified success and 9% unmitigated failure, with no difference between the treatment arms. Treatment response and adverse event rates were not correlated. In RACAT, 309 of 353 patients had response data at 48 weeks: 6% of patients experienced unqualified success and 11% unmitigated failure, with no differences between the treatment arms. Response and adverse event rates were negatively correlated: frequency of AE and SAE increased as response decreased (p=0.008).
CONCLUSION: We found some evidence that clinical response may be reduced by the co-occurrence of adverse events. This article is protected by copyright. All rights reserved.
METHODS: Treatment of Early Aggressive RA (TEAR) and the RA Comparison of Active Therapies (RACAT) randomized trial outcomes for safety were defined according to OMERACT as no events, non-serious events, and serious events. Treatment efficacy was defined as good, moderate, or no response. A good treatment response without any events was labeled an 'unqualified success', and no treatment response but at least one adverse event an 'unmitigated failure'. Chi-square or exact tests assessed the association between benefit and harm, as appropriate.
RESULTS: In TEAR, 612 of 755 patients had response data at 48 weeks: 14% of patients experienced unqualified success and 9% unmitigated failure, with no difference between the treatment arms. Treatment response and adverse event rates were not correlated. In RACAT, 309 of 353 patients had response data at 48 weeks: 6% of patients experienced unqualified success and 11% unmitigated failure, with no differences between the treatment arms. Response and adverse event rates were negatively correlated: frequency of AE and SAE increased as response decreased (p=0.008).
CONCLUSION: We found some evidence that clinical response may be reduced by the co-occurrence of adverse events. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app